跳至主要内容
临床试验/NCT03151382
NCT03151382
Unknown
4 期

A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease

Zhejiang Provincial People's Hospital0 个研究点目标入组 30 人开始时间: 2017年5月20日最近更新:

概览

阶段
4 期
入组人数
30
主要终点
Change of ADAS-cog total score

概览

简要总结

Objective: Evaluation the improvement of the cognitive function of tandospirone add-on treatment on patients with AD comorbid anxiety.

Number of Patients: 30

Methodology: Randomized, open-label, parallel-group

Assigned Interventions: Experimental: Tandospirone, 30-60 mg/d + Donepezil, 10 mg/d; Control group: Donepezil, 10 mg/d.

Effect Evaluation: Primary Outcome: Change from baseline in ADAS-cog total score at week 12; NPI scale total score at week 12;

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
55 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 55-80 years old (including 55 and 80), male or female, sufficient vision, hearing and general health to complete the follow-up and assessment;
  • Patients who were diagnosed with AD according to the DSM-IV;
  • MMSE score \> 10 and ≤ 24;
  • HAMA score \> 8;
  • HAMD score ≤ 7;
  • Brain CT or MRI supports the diagnosis of AD;
  • Provide written informed consent by the patient himself and his family member or guardian.

排除标准

  • Dementia from any other cause;
  • Brain MRI showed that the diameter of hyperintense lesions in T2-FLAIR sequences were larger than 5mm;
  • Patients with significant cardiac, pulmonary, hepatic, renal, or hematologic disease;
  • Any primary neurologic or psychiatric disease other than AD;
  • Mental disorders due to substance abuse;
  • Participation in other clinical studies within the last 30 days;
  • History of alcohol or substance abuse or dependence within the past year;
  • Pregnant or breastfeeding, or of child-bearing potential during the study.

研究组 & 干预措施

Experimental group

Experimental

干预措施: Tandospirone Citrate (Drug)

Experimental group

Experimental

干预措施: Donepezil Hydrochloride (Drug)

Control group

Other

干预措施: Donepezil Hydrochloride (Drug)

结局指标

主要结局

Change of ADAS-cog total score

时间窗: week 12

Change from baseline in ADAS-cog total score at week 12

NPI scale total score

时间窗: week 12

NPI scale total score at week 12

次要结局

  • HAMA total score(week 12)
  • relative power(week 12)
  • FAB score(week 12)
  • the image of PET(week 12)
  • MMSE score(week 12)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Enyan Yu

Secretary of Party Committee

Zhejiang Provincial People's Hospital

相似试验